Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study.

Background: Elderly people aged over 85 years were among the first groups to receive the BNT162b2 mRNA Covid-19 vaccine in Greece according to the national priority assignment policy.

Aim: The aim of this study was to provide useful insight into the antibody generation taking place post-immunization in elderly individuals aged over 85.

Methods: In the first phase of our study, antibody levels were monitored in a total of 400 participants, while our final sample consisted of 297 subjects.